drugset / Trial / NCT00132379
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer \[NSCLC\]), can be given to patients with NSCLC without causing unacceptable side effects.
Timeline
- Start
- 2005-11
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naptumomab estafenatox | Protein / enzyme biologic | 10.3 ug/kg | Intravenous |
| Subject | Naptumomab estafenatox | Protein / enzyme biologic | 16.5 ug/kg | Intravenous |
| Subject | Naptumomab estafenatox | Protein / enzyme biologic | 22 ug/kg | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |